Last updated: July 05, 2026

Application No. 18/381,258

CAR-T CONSTRUCTS COMPRISING A NOVEL CD19 BINDER COMBINED WITH IL18 AND METHODS OF USING THE SAME

Non-Final OA

Filed

Oct 18, 2023

Priority

Oct 18, 2022 — provisional 63/417,216 +1 more

Examiner

HAMA, JOANNE

Art Unit

1647

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

The Trustees of the University of Pennsylvania

OA Round

1 (Non-Final)

This examiner grants 24% of cases after interview

— +37.3% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 257 resolved cases, 2023–2026

Examiner Intelligence

HAMA, JOANNE View full profile →

Grants only 24% of cases

Career Allowance Rate

63 granted / 257 resolved

-35.5% vs TC avg

Strong +37% interview lift

Without

With

+37.3%

Interview Lift

resolved cases with interview

Typical timeline

3y 8m

Avg Prosecution

30 currently pending

Career history

269

Total Applications

across all art units

Statute-Specific Performance

§101

4.7%

-35.3% vs TC avg

§103

57.8%

+17.8% vs TC avg

§102

8.9%

-31.1% vs TC avg

§112

14.2%

-25.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 257 resolved cases

Prosecution Timeline

Oct 18, 2023

Application Filed

Apr 06, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/273,212

Patent 12648929

COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING FILARIAL DISEASE

5y 3m to grant Granted Jun 09, 2026

17/631,797

Patent 12595300

ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODY AND USE THEREOF

4y 2m to grant Granted Apr 07, 2026

17/843,232

Patent 12559553

IL-31 MODULATORS FOR TREATING FXR-INDUCED PRURITUS

3y 8m to grant Granted Feb 24, 2026

17/808,379

Patent 12553897

USE OF CIRCULATING INTERLEUKIN-18 FOR PROGNOSTICATING AND TREATING RECURRENCE IN EARLY STAGE NON-SMALL CELL LUNG CANCER

3y 8m to grant Granted Feb 17, 2026

15/733,313

Patent 12168688

ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1

4y 5m to grant Granted Dec 17, 2024

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

24%

Grant Probability

62%

With Interview (+37.3%)

3y 8m (~11m remaining)

Median Time to Grant

Low

PTA Risk

Based on 257 resolved cases by this examiner. Grant probability derived from career allowance rate.